Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.48 |
| ▸ | NSD2 | O96028 | 2/20 | 0.47 |
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.46 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.43 |
| ▸ | RBP4 | P02753 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19260615 | 0.88 | TLR9 (0.49) | TLR9TLR7NSD2EHMT2EPHA2 | |
| SCHEMBL19260529 | 0.84 | EHMT2 (0.49) | NSD2EHMT2 | |
| Trifluoroacetic Acid SCHEMBL20720749 | 0.83 | KIT (0.47) | EHMT2 | |
| SCHEMBL19260534 | 0.83 | KIT (0.54) | EHMT2 | |
| Trifluoroacetic Acid SCHEMBL20720740 | 0.80 | KIT (0.49) | EHMT2 | |
| SCHEMBL19260530 | 0.80 | KIT (0.55) | EHMT2 | |
| SCHEMBL3132645 | 0.77 | EPHA2 (0.55) | NSD2EPHA2ERBB2EPHB4PIK3CD | |
| SCHEMBL2459163 | 0.76 | HTR6 (0.54) | KDM4EPKMRBP4 | |
| SCHEMBL23668017 | 0.75 | KIT (0.53) | EHMT2 | |
| SCHEMBL20952048 | 0.75 | NSD2 (0.52) | TLR9TLR7NSD2EHMT2EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3416963-B1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2019-02-14 | — | — | US | disclosed |
| EP-3416963-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017142947-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047981-A1 | HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | TLR9 3384/4885TLR7 4549/4885NSD2 127/4885 |
| US-11254651-B2 | Histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | TLR9 3384/4885TLR7 4549/4885NSD2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.